Publications
Found 1 results
Filters: Author is Z.F. Yang [Clear All Filters]
“Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China”, vol. 9, pp. 1844-1851, 2010.
, Bertilsson L (1995). Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 29: 192-209.
http://dx.doi.org/10.2165/00003088-199529030-00005
PMid:8521680
Chen L, Qin S, Xie J, Tang J, et al. (2008). Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9: 691-702.
http://dx.doi.org/10.2217/14622416.9.6.691
PMid:18518848
de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, et al. (1994a). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269: 15419-15422.
PMid:8195181
de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, et al. (1994b). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46: 594-598.
PMid:7969038
Desta Z, Zhao X, Shin JG and Flockhart DA (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41: 913-958.
http://dx.doi.org/10.2165/00003088-200241120-00002
PMid:12222994
Evans WE and Johnson JA (2001). Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2: 9-39.
http://dx.doi.org/10.1146/annurev.genom.2.1.9
PMid:11701642
Gardiner SJ and Begg EJ (2006). Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 58: 521-590.
http://dx.doi.org/10.1124/pr.58.3.6
PMid:16968950
Goldstein JA (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52: 349-355.
http://dx.doi.org/10.1046/j.0306-5251.2001.01499.x
PMid:11678778 PMCid:2014584
Goldstein JA, Ishizaki T, Chiba K, de Morais SM, et al. (1997). Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7: 59-64.
http://dx.doi.org/10.1097/00008571-199702000-00008
PMid:9110363
Goto T, Miura M, Murata A, Terata K, et al. (2010). Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria. Clin. Chim. Acta 411: 1375-1377.
http://dx.doi.org/10.1016/j.cca.2010.04.014
PMid:20420818
Hitchen L (2006). Adverse drug reactions result in 250,000 UK admissions a year. BMJ 332: 1109.
http://dx.doi.org/10.1136/bmj.332.7550.1109
PMid:16690649 PMCid:1459569
Kesavan R, Narayan SK and Adithan C (2010). Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur. J. Clin. Pharmacol. 66: 689-696.
http://dx.doi.org/10.1007/s00228-010-0817-2
PMid:20390258
Kimura S, Pastewka J, Gelboin HV and Gonzalez FJ (1987). cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res. 15: 10053-10054.
http://dx.doi.org/10.1093/nar/15.23.10053
PMid:3697070 PMCid:306558
Lee CR, Goldstein JA and Pieper JA (2002). Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12: 251-263.
http://dx.doi.org/10.1097/00008571-200204000-00010
PMid:11927841
Leung AY, Chow HC, Kwong YL, Lie AK, et al. (2001). Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 98: 2584-2587.
http://dx.doi.org/10.1182/blood.V98.8.2584
PMid:11588061
Liou YH, Lin CT, Wu YJ and Wu LS (2006). The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J. Hum. Genet. 51: 857-863.
http://dx.doi.org/10.1007/s10038-006-0034-0
PMid:16924387
Miners JO and Birkett DJ (1998). Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45: 525-538.
http://dx.doi.org/10.1046/j.1365-2125.1998.00721.x
PMid:9663807 PMCid:1873650
Nasu K, Kubota T and Ishizaki T (1997). Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7: 405-409.
http://dx.doi.org/10.1097/00008571-199710000-00011
PMid:9352578
Niu CY, Luo JY and Hao ZM (2004). Genetic polymorphism analysis of cytochrome P4502C19 in Chinese Uigur and Han populations. Chin. J. Dig. Dis. 5: 76-80.
http://dx.doi.org/10.1111/j.1443-9573.2004.00160.x
PMid:15612662
Roh HK, Dahl ML, Tybring G, Yamada H, et al. (1996). CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6: 547-551.
http://dx.doi.org/10.1097/00008571-199612000-00008
PMid:9014204
Ross AM, Gao R, Coyne KS, Chen J, et al. (2001). A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. Am. Heart J. 142: 244-247.
http://dx.doi.org/10.1067/mhj.2001.116963
PMid:11479462
Sanderson S, Emery J and Higgins J (2005). CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7: 97-104.
http://dx.doi.org/10.1097/01.GIM.0000153664.65759.CF
PMid:15714076
Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, et al. (1996). The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341-349.
http://dx.doi.org/10.1097/00008571-199608000-00007
PMid:8873220
Xie HG, Prasad HC, Kim RB and Stein CM (2002). CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54: 1257-1270.
http://dx.doi.org/10.1016/S0169-409X(02)00076-5
Yu HC, Chan TY, Critchley JA and Woo KS (1996). Factors determining the maintenance dose of warfarin in Chinese patients. QJM 89: 127-135.
http://dx.doi.org/10.1093/qjmed/89.2.127
PMid:8729554
Zhang S, Dong Z, Tang L, Zhou Q, et al. (2002). Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19: 52-54.
PMid:11836688
Zhou SF, Liu JP and Chowbay B (2009a). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 41: 89-295.
http://dx.doi.org/10.1080/03602530902843483
PMid:19514967
Zhou SF, Zhou ZW, Yang LP and Cai JP (2009b). Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr. Med. Chem. 16: 3480-3675.
http://dx.doi.org/10.2174/092986709789057635
PMid:19515014